Focused articles on AI visibility, SEO, and sustainable growth for life sciences companies.
Watch how VayoMed’s SIUU status review handles FDA implementation wording, OMB collection approvals and the review record for scientific communications.
Watch an overview of EU AI Act Article 50, substantive human review and editorial responsibility for AI-assisted public-interest content.
Get the latest insights on AI visibility and life sciences marketing delivered to your inbox.
No spam. Unsubscribe anytime.
Use FDA guidance, enforcement cases and classification data to distinguish wellness, device and software claims across websites, interfaces and communications.
Watch how legal names, brands and local holders affect cross-market findability, using a matched cohort of NIH device awardees with FDA clearance.
Watch how one durable product page can connect FDA clearance wording, public evidence, news updates and buyer inquiries across your digital presence.
Separate Form 6-K filing rules, English translations and incorporation by reference from the life-sciences communications workflow and its review record.
Watch how a 40-market ultrasound model separates market ranking from language investment, with practical steps for choosing sustainable website locales.
Watch a practical breakdown of salary, benefits, part-time roles and coordination costs when building an in-house growth operation for life sciences.
Watch the differences between FDA clearance, De Novo grants and PMA approval, and how to keep device status wording consistent across public communications.
Watch how a life sciences website can help buyers verify FDA clearance, find product evidence, and understand your company in search and AI answers.
Reconcile FDA’s SIUU implementation notice with later OMB approvals, then classify life-sciences communications and preserve review across derivative content.
Compare life-sciences filings from the year 2026: required announcement text, other exhibits, furnished versus filed treatment and disclosure deadlines.
EU AI Act Article 50(4) applies from 2 August 2026. Sort five AI-written life-sciences outputs and see the review record that lets a disease page skip the label.
A 40-market evidence model turns trade, access, language, digital readiness, and delivery constraints into a practical website localization sequence.
We joined NIH device awards, FDA 510(k)s, federal contracts, and ten public registers to measure the public-evidence gap after funding and clearance.
We rebuilt our own $200,000-$300,000 comparison claim from federal wage data. A realistic in-house configuration costs $220,888 a year - and here is every line of the arithmetic.
A 60-company audit reveals where newly cleared MedTech websites break between FDA records, product findability, regulatory evidence, and buyer inquiry.
